Zoetis Q3 2026 Results: Net Income $591 Million on Revenue of $2.39 Billion
- US stocks
- Earnings
- Health Care

Zoetis (NYSE: ZTS) reported its results for the third quarter of 2026, with GAAP revenue of $2.39 billion and GAAP net income of $591.0 million, it said on 5 Nov 2026. Diluted EPS was $1.44 on a GAAP basis, and adjusted diluted EPS, a company-defined measure that excludes certain items, was $1.75.
Key highlights
- Revenue (GAAP): $2.39 billion, down 1.3% YoY and 3.1% QoQ
- Net income (GAAP): $591.0 million, down 18.0% YoY and 14.5% QoQ
- Diluted EPS (GAAP): $1.44, down 11.7% YoY
- Adjusted diluted EPS (company-defined): $1.75
Summary
| Particulars | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,391.0 | 2,422.0 | -1.3% | 2,468.0 | -3.1% |
| 591.0 | 721.0 | -18.0% | 691.0 | -14.5% | |
| Net income margin | 24.72% | 29.77% | -5.05 pp | 28.00% | -3.28 pp |
| Diluted EPS ($) | 1.44 | 1.63 | -11.7% | 1.65 | -12.7% |
Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
The table shows GAAP revenue of $2.39 billion, down 1.3% from the third quarter of 2025 and 3.1% from the second quarter of 2026. GAAP net income of $591.0 million was 18.0% lower than a year earlier and 14.5% lower than in the second quarter.
Net income was 24.7% of revenue this quarter, against 29.8% a year earlier, a fall of 5.1 percentage points.
Adjusted figures exclude $129 million of items
Adjusted net income, a company-defined measure, was $720 million in the quarter, down 5% on a reported basis from $754 million a year earlier. The company said the gap between GAAP and adjusted net income, $129 million, comes from purchase accounting effects, acquisition and divestiture costs, and items it calls significant.
Certain significant items included $89.0 million of asset impairment charges. The company said the in-process R&D part of that charge came from updated development and commercial assumptions for assets acquired from PetMedix in 2023.
U.S. revenue fell while International rose
U.S. segment revenue was $1.25 billion, down 6% on both a reported and an organic operational basis. The company said U.S. Companion Animal revenue fell 8%, pointing to macro price sensitivity, competitive pressure in dermatology and generic competition. U.S. Livestock revenue rose 5%.
International segment revenue was $1.12 billion, up 4% on both bases. International Livestock revenue rose 8% on a reported basis, and the company named growth in cattle and fish. Companion Animal revenue across both segments was $1,565 million, down 5%.
Revenue outlook narrowed and adjusted EPS raised for 2026
The company now expects 2026 revenue of $9.220 billion to $9.320 billion, against a prior range of $9.120 billion to $9.320 billion. It now expects adjusted net income of $2.600 billion to $2.640 billion, against a prior $2.570 billion to $2.620 billion.
Adjusted diluted EPS is now guided to $6.25 to $6.35, up from $6.15 to $6.25. Reported diluted EPS is guided to $5.50 to $5.60, against a prior $5.55 to $5.65. The company said its guidance uses foreign exchange rates as of 20 Oct 2026.
Inference
Diluted weighted-average shares were 411.6 million in the quarter, against 443.2 million a year earlier. The release gives no share buyback or dividend amounts and no cash flow figures.
The next dated step in the release is the availability of Convenia RTU for Dogs to veterinarians in the first quarter of 2027, with select 2027 approvals now expected in Q4 2026.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

